News Enbrel unlikely to face Novartis rival until 2018 Amgen arguing that US patent will last until 2029.
News Novartis less exposed to US pricing pressure, says Jimenez Europe and Asia account for a large share of company's income.
News Mallinckrodt pays US authorities $100m in pricing case Price of epilepsy drug increased 85,000% since 2001, says FTC.
News Pharma braces as Trump begins dismantling Obamacare Trump focused on reforming or repealing Obamacare
News Don't cut prices, cut taxes, pharma CEO tells Trump Industry plays key role in job creation too, says Novartis CEO.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
